Ieq Capital LLC Has $3.16 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Ieq Capital LLC lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 7,650 shares of the company’s stock after selling 243 shares during the period. Ieq Capital LLC’s holdings in IDEXX Laboratories were worth $3,163,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in IDXX. FSA Wealth Management LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares during the last quarter. Retirement Wealth Solutions LLC bought a new position in IDEXX Laboratories during the fourth quarter valued at about $31,000. Ashton Thomas Securities LLC bought a new position in IDEXX Laboratories during the third quarter valued at about $37,000. Finally, Kestra Investment Management LLC bought a new position in IDEXX Laboratories during the fourth quarter valued at about $38,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on IDXX shares. Barclays boosted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners started coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target on the stock. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th. Finally, Piper Sandler boosted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $533.75.

Insider Activity

In related news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now directly owns 905 shares in the company, valued at $380,498.20. This represents a 27.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 13,330 shares of company stock worth $6,161,276. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Down 0.0 %

IDXX stock opened at $452.77 on Friday. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The firm has a market cap of $37.08 billion, a P/E ratio of 42.43, a P/E/G ratio of 3.41 and a beta of 1.37. The business’s 50 day moving average is $431.92 and its 200-day moving average is $452.40. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.